Oppenheimer raised the firm’s price target on AngioDynamics (ANGO) to $16 from $13 and keeps an Outperform rating on the shares. AngioDynamics’ Q2 sales exceeded the Street’s estimates, with MedTech sales the upside driver, with particular strength in mechanical thrombectomy, the analyst tells investors in a research note. NanoKnife is also positioned for acceleration with prostate approval on hand, the firm says.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics price target raised to $15 from $14 at H.C. Wainwright
- AngioDynamics price target raised to $15 from $12 at Canaccord
- AngioDynamics, Inc. Reports Growth in Med Tech Segment
- Morning Movers: AngioDynamics jumps following results and guidance raise
- AngioDynamics Hosts Virtual NanoKnife Investor Event